Oramed Pharmaceuticals (Nasdaq:ORMP) announced today that it received a new patent for its oral diabetes treatment.
The U.S. Patent and Trademark Office (USPTO) granted a patent titled “Methods and Compositions for Treating Diabetes.” This patent extends a patent previously granted in May 2022.
According to a news release, the patent addresses methods and compositions for treating diabetes mellitus. This extends to oral pharmaceutical compositions comprising insulin in combination with glucagon-like peptide 1 (GLP-1).
“With the topline data for our first Phase 3 oral insulin trial expected soon, we continue to further fortify Oramed’s leading position with respect to intellectual property assets addressing the oral delivery of therapeutic proteins currently only available via injection,” said Oramed CEO Nadav Kidron.
Oramed aims to change the treatment of diabetes with its ORMD-0801 oral insulin capsule. The capsule is currently under evaluation in two pivotal Phase 3 trials. The company recently inked a deal to commercialize the oral insulin treatment in the Republic of Korea.
The company’s oral GLP-1 analog capsule, called ORMD-0901, is also under development.